Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying a novel drug called ALRN-6924 as a possible treatment for
resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia.
The drugs involved in this study are:
- ALRN-6924
- Cytarabine (for patients with leukemia only)
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Aileron Therapeutics, Inc. Cookies for Kids' Cancer TeamConnor Childhood Cancer Foundation